Vaxart (VXRT) Competitors

Vaxart (NASDAQ:VXRT) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Do analysts rate VXRT or PRTA?

Vaxart presently has a consensus target price of $3.00, suggesting a potential upside of 743.17%. Prothena has a consensus target price of $31.50, suggesting a potential upside of 362.56%. Given Vaxart's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vaxart is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Prothena	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media refer more to VXRT or PRTA?

In the previous week, Prothena had 2 more articles in the media than Vaxart. MarketBeat recorded 4 mentions for Prothena and 2 mentions for Vaxart. Vaxart's average media sentiment score of 1.32 beat Prothena's score of 0.21 indicating that Vaxart is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxart	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of VXRT or PRTA?

18.0% of Vaxart shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 2.9% of Vaxart shares are held by insiders. Comparatively, 9.2% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has better valuation and earnings, VXRT or PRTA?

Vaxart has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxart	$47.40M	1.72	-$66.95M	-$0.27	-1.32
Prothena	$137.94M	2.66	-$122.31M	-$2.08	-3.27

Which has more risk & volatility, VXRT or PRTA?

Vaxart has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Prothena has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500.

Is VXRT or PRTA more profitable?

Prothena has a net margin of -79.94% compared to Vaxart's net margin of -122.63%. Prothena's return on equity of -21.61% beat Vaxart's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxart	-122.63%	-91.89%	-38.40%
Prothena	-79.94%	-21.61%	-19.32%

Summary

Prothena beats Vaxart on 9 of the 16 factors compared between the two stocks.